• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer.

作者信息

Iwamoto Genta, Kawahara Takashi, Yokomizo Yumiko, Miyoshi Yasuhide, Yao Masahiro, Uemura Hiroji

机构信息

Department of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.

Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.

出版信息

Asian J Urol. 2021 Jul;8(3):332-334. doi: 10.1016/j.ajur.2020.05.006. Epub 2020 May 22.

DOI:10.1016/j.ajur.2020.05.006
PMID:34401340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8356057/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24a5/8356057/a24206c9a93d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24a5/8356057/a24206c9a93d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24a5/8356057/a24206c9a93d/gr1.jpg

相似文献

1
The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer.前列腺特异性抗原最低点时的中性粒细胞与淋巴细胞比值可预测去势抵抗性前列腺癌的发生时间。
Asian J Urol. 2021 Jul;8(3):332-334. doi: 10.1016/j.ajur.2020.05.006. Epub 2020 May 22.
2
High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.高中性粒细胞与淋巴细胞比值预示着接受多西他赛化疗的去势抵抗性前列腺癌患者临床预后不良。
Int J Urol. 2015 Sep;22(9):827-33. doi: 10.1111/iju.12839. Epub 2015 Jun 18.
3
Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.雄激素剥夺治疗期间前列腺特异性抗原动力学曲线作为去势抵抗性前列腺癌的预后因素
Urol Oncol. 2015 May;33(5):203.e1-9. doi: 10.1016/j.urolonc.2015.01.017. Epub 2015 Feb 26.
4
PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.在接受多西他赛治疗的转移性去势抵抗性前列腺癌患者中，初始雄激素剥夺治疗期间的前列腺特异性抗原（PSA）最低点及达到PSA最低点的时间作为预后因素。
Andrologia. 2021 May;53(4):e13916. doi: 10.1111/and.13916. Epub 2021 Feb 16.
5
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.前列腺特异性抗原对延迟联合雄激素阻断治疗的反应预测了去势抵抗性前列腺癌患者后续雌激素和多西他赛治疗后的生存。
BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.
6
PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.PSA 时间至最低点作为一线多西他赛治疗去势抵抗性前列腺癌的预后因素：来自中国前列腺癌联盟患者的多中心验证。
Urol Oncol. 2020 Jan;38(1):2.e11-2.e17. doi: 10.1016/j.urolonc.2019.07.014. Epub 2019 Oct 28.
7
Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.去势抵抗性前列腺癌患者在抗雄激素撤药期间前列腺特异性抗原（PSA）呈指数上升，预示着多西他赛化疗后PSA会出现激增。
Yonsei Med J. 2015 Mar;56(2):368-74. doi: 10.3349/ymj.2015.56.2.368.
8
Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.初始雄激素剥夺治疗期间 PSA 最低值及达到 PSA 最低值时间对转移性去势抵抗性前列腺癌患者预后的影响。
World J Urol. 2019 Nov;37(11):2365-2373. doi: 10.1007/s00345-019-02664-3. Epub 2019 Feb 7.
9
Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.前列腺特异性抗原半衰期和前列腺特异性抗原倍增时间作为转移性前列腺癌雄激素剥夺治疗反应的预测指标。
J Urol. 2009 Jun;181(6):2520-4; discussion 2525. doi: 10.1016/j.juro.2009.01.104. Epub 2009 Apr 16.
10
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.恩扎卢胺治疗下非转移性去势抵抗性前列腺癌患者的前列腺特异性抗原进展：任何前列腺特异性抗原的升高都可能需要更密切的监测。
Eur Urol. 2020 Dec;78(6):847-853. doi: 10.1016/j.eururo.2020.08.025. Epub 2020 Oct 1.

引用本文的文献

1
A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.高中性粒细胞与淋巴细胞比值是接受醋酸阿比特龙或恩扎卢胺治疗的去势抵抗性前列腺癌患者预后不良的一个因素。
BMC Cancer. 2020 Sep 25;20(1):919. doi: 10.1186/s12885-020-07410-2.

本文引用的文献

1
Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.高危非肌肉浸润性膀胱癌患者的系统性炎症标志物与肿瘤学结局。
Eur Urol Oncol. 2018 Oct;1(5):403-410. doi: 10.1016/j.euo.2018.06.006. Epub 2018 Jul 13.
2
Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients.中性粒细胞、血小板和嗜酸性粒细胞与淋巴细胞比值可预测低风险前列腺癌患者的 Gleason 评分升级情况。
Urol Int. 2019;102(1):43-50. doi: 10.1159/000494259. Epub 2018 Nov 8.
3
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
多机构 T1G3 非肌层浸润性膀胱癌患者队列中中性粒细胞与淋巴细胞比值的验证。
Clin Genitourin Cancer. 2018 Dec;16(6):445-452. doi: 10.1016/j.clgc.2018.07.003. Epub 2018 Jul 6.
4
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.阿比特龙联合泼尼松治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4.
5
Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance.中性粒细胞与淋巴细胞比值在预测适合主动监测的低风险前列腺癌患者 Gleason 评分升级和疾病分期进展中的作用。
Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E383-E387. doi: 10.5489/cuaj.3550. Epub 2016 Nov 10.
6
Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.中性粒细胞与淋巴细胞比值在前列腺癌中的预后意义：来自16266例患者的证据。
Sci Rep. 2016 Feb 25;6:22089. doi: 10.1038/srep22089.
7
Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer.治疗前中性粒细胞与淋巴细胞比值可预测转移性前列腺癌患者的预后。
BMC Cancer. 2016 Feb 16;16:111. doi: 10.1186/s12885-016-2134-3.
8
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.中性粒细胞减少症作为转移性去势抵抗性前列腺癌男性患者基于多西紫杉醇化疗的潜在药效动力学标志物。
Clin Genitourin Cancer. 2012 Dec;10(4):239-45. doi: 10.1016/j.clgc.2012.06.004. Epub 2012 Sep 19.
9
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.卵巢癌的进展受树突状细胞表型变化的控制。
J Exp Med. 2012 Mar 12;209(3):495-506. doi: 10.1084/jem.20111413. Epub 2012 Feb 20.
10
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.CD4+ CD25+ 调节性T细胞控制癌症患者抗原特异性CD4+ 辅助性T细胞反应的诱导。
Blood. 2005 Aug 1;106(3):1008-11. doi: 10.1182/blood-2005-02-0607. Epub 2005 Apr 19.